SEARCHOTHERendocrinology, preclinical research

other·endocrinology, preclinical research, biomedical research, gastroenterology, nutrition·PMC10059022

Phloretamide Prevent Hepatic and Pancreatic Damage in Diabetic Male Rats by Modulating Nrf2 and NF-κB

Nutrients · 5 authors, 1 centre

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This animal study tested phloretamide in male rats with streptozotocin-induced diabetes. Phloretamide significantly reduced pancreatic damage, liver fat, and blood sugar in a dose-dependent manner over 12 weeks.

Full summary

745 CHARS

This preclinical study investigated phloretamide (100 or 200 mg/kg) in male rats with streptozotocin-induced diabetes over 12 weeks. The central results showed that phloretamide dose-dependently attenuated pancreatic β-cell damage, reduced fasting glucose, increased insulin levels, and improved hepatic enzyme profiles (increased hexokinase, decreased glucose-6 phosphatase and fructose-1,6-bisphosphatase 1). It also reduced hepatic and serum lipids, liver cell ballooning, lipid peroxidation, and inflammatory markers (TNF-α, IL-6, NF-κB), while increasing antioxidant levels (GSH, SOD, CAT, HO-1) and Nrf2. The findings suggest phloretamide may ameliorate diabetes-associated liver steatosis via antioxidant and anti-inflammatory mechanisms.

STUDY TYPE

other

SPECIALTY

endocrinology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10059022

Phloretamide Prevent Hepatic and Pancreatic Damage in Diabetic Male Rats by Modulating Nrf2 and NF-κB

Nutrients

READ THE FULL PAPER

ABSTRACT

This study examined the effect of phloretamide, a metabolite of phloretin, on liver damage and steatosis in streptozotocin-induced diabetes mellitus (DM) in rats. Adult male rats were divided into two groups: control (nondiabetic) and STZ-treated rats, each of which was further treated orally with the vehicle phloretamide 100 mg or 200 mg. Treatments were conducted for 12 weeks. Phloretamide, at both doses, significantly attenuated STZ-mediated pancreatic β-cell damage, reduced fasting glucose, and stimulated fasting insulin levels in STZ-treated rats. It also increased the levels of hexokinase, which coincided with a significant reduction in glucose-6 phosphatase (G-6-Pase), and fructose-1,6-bisphosphatase 1 (PBP1) in the livers of these diabetic rats. Concomitantly, both doses of phloretamide reduced hepatic and serum levels of triglycerides (TGs) and cholesterol (CHOL), serum levels of low-density lipoprotein cholesterol (LDL-c), and hepatic ballooning. Furthermore, they reduced levels of lipid peroxidation, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), mRNA, and total and nuclear levels of NF-κB p65, but increased mRNA levels, total and nuclear levels of Nrf2, as well as levels of reduced glutathione (GSH), superoxide dismutase (SOD-1), catalase (CAT), and heme-oxygenase-1 (HO-1) in the livers of diabetic rats. All of these effects were dose-dependent. In conclusion, phloretamide is a novel drug that could ameliorate DM-associated hepatic steatosis via its powerful antioxidant and anti-inflammatory effects. Mechanisms of protection involve improving the β-cell structure and hepatic insulin action, suppressing hepatic NF-κB, and stimulating hepatic Nrf2.

CITATION EXPORT

Rasha Al-Hussan, Nawal A. Albadr, Ghedeir M. Alshammari et al.. Phloretamide Prevent Hepatic and Pancreatic Damage in Diabetic Male Rats by Modulating Nrf2 and NF-κB. Nutrients. (2023). https://doi.org/10.3390/nu15061456

AUTHORS

5 · 1 CENTRES

Rasha Al-Hussan, Nawal A. Albadr, Ghedeir M. Alshammari, Soheir A. Almasri, Mohammed Abdo Yahya

Department of Food Science and Nutrition, College of Food and Agricultural Sciences, King Saud University, Riyadh 11451, Saudi Arabia

EDITOR / REVIEWER

Joanna Bartkowiak-Wieczorek, Edyta Mądry